PAND Skyrocketed
PAND (PAND:NASDAQ) shot up at $21.94, a gain of 47.7%. The stock got featured on our News Catalysts scanner on Mon 04 Jan 21 at 10:59 AM in the 'BIOTECH' category. From Thu 17 Dec 20, the stock recorded 33.33% Up Days and 30.00% Green Days
The share price of the company has been moving sideways in recent weeks.
About PAND (PAND:NASDAQ)
Pandion Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. Its pipeline products are PT101, PT627, PT001, and others. The firm has combined a network-based conceptualization of the immune system in advanced protein engineering to develop TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform.
Top 10 Gainers:
- Check-Cap Ltd. (CHEK:NASDAQ), 215.22%
- Bionano Genomics, Inc. (BNGO:NASDAQ), 133.77%
- Jaguar Health, Inc. (JAGX:NASDAQ), 118.4%
- TransEnterix, Inc. (TRXC:NYSEMKT), 87.2%
- The9 Limited (NCTY:NASDAQ), 87.01%
- ViewRay, Inc. (VRAY:NASDAQ), 67.8%
- Ocugen, Inc. (OCGN:NASDAQ), 67.76%
- Zomedica Pharmaceuticals Corp. (ZOM:NYSEMKT), 51.78%
- PAND (PAND:NASDAQ), 47.74%
- KSPN (KSPN:NASDAQ), 39.23%